#### The citrate transporter SLC13A5 as a therapeutic target for kidney disease: 1 evidence from Mendelian randomization to inform drug development 2 3 Dipender Gill BMBCh PhD<sup>1,2</sup>, Loukas Zagkos PhD<sup>1</sup>, Rubinder Gill MSc<sup>2</sup>, Thomas Benzing 4 MD<sup>3,4</sup>, Jens Jordan MD<sup>5,6</sup>, Andreas L. Birkenfeld MD<sup>7-9</sup>, Stephen Burgess PhD<sup>10</sup>, Grit Zahn 5 $PhD^{11}$ 6 7 8 1. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College 9 London, London, United Kingdom. 10 2. Primula Group Ltd, London, United Kingdom. 3. Department II of Internal Medicine and Center for Molecular Medicine Cologne (CMMC), 11 12 University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, 13 Germany. 4. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases 14 15 (CECAD), University of Cologne, Germany. 16 5. Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany. 17 6. Medical Faculty, University of Cologne, Cologne, Germany. 18 7. Department of Diabetology Endocrinology and Nephrology, Internal Medicine IV, University 19 Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany. 20 8. Division of Translational Diabetology, Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Eberhard Karls University Tübingen, Tübingen, 21 22 Germany, a partner of the German Center for Diabetes Research (DZD e.V.). 23 9. Department of Diabetes, School of Life Course Science and Medicine, King's College London, 24 London, United Kingdom. 25 10. Medical Research Council Biostatistics Unit at the University of Cambridge, Cambridge, 26 United Kingdom. 27 11. Eternygen GmbH, Berlin, Germany. 28 29 **Corresponding author details:** 30 Dr Dipender Gill 31 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, 32 London, United Kingdom 33 Telephone: +44 7904843810 34 E-mail: dipender.gill@imperial.ac.uk 35 36 37 Manuscript word count: 3,408

1

#### 38 Abstract (386 words)

- 39 Background: Solute carrier family 13 member 5 (SLC13A5) is a Na<sup>+</sup>-coupled citrate co-transporter
- 40 that mediates the entry of extracellular citrate into the cytosol. SLC13A5 inhibition has been
- 41 proposed as a therapeutic target for reducing progression of kidney disease via its effects on citrate
- 42 metabolism. However, evidence of its efficacy in humans is limited. The aim of this study was to
- 43 leverage the Mendelian randomization paradigm to gain insight into the effects of SLC13A5 inhibition
- 44 in humans, towards prioritizing and informing clinical development efforts.
- 45 Methods: The primary Mendelian randomization analyses investigated the effect of SLC13A5
- 46 inhibition on measures of kidney function, including creatinine and cystatin C based measures of
- 47 estimated glomerular filtration rate (creatinine-eGFR and cystatin C-eGFR), blood urea nitrogen
- 48 (BUN), urine albumin-creatinine ratio (uACR), and risk of chronic kidney disease and
- 49 microalbuminuria. Secondary analyses included a paired plasma and urine metabolome-wide
- 50 association study, investigation of secondary traits related to SLC13A5 biology, a phenome-wide
- association study (PheWAS), and a proteome-wide association study. All analyses were compared to
- 52 the effect of genetically predicted plasma citrate levels using variants selected from across the
- 53 genome, and statistical sensitivity analyses robust to the inclusion of pleiotropic variants were also
- 54 performed. Data were obtained from large scale genetic consortia and biobanks, with sample sizes
- ranging from 5,023 to 1,320,016 individuals.
- 56 Results: We found evidence of associations between genetically proxied SLC13A5 inhibition and
- 57 higher creatinine-eGFR (p=0.002), cystatin C-eGFR (p=0.005), and lower BUN (p= $3\times 10^{-3}$ ). Statistical
- sensitivity analyses robust to the inclusion of pleiotropic variants suggested that these effects may be
- 59 a consequence of higher plasma citrate levels. There was no strong evidence of associations of
- 60 genetically proxied SLC13A5 inhibition with uACR or risk of CKD or microalbuminuria. Secondary
- analyses also identified evidence of associations with higher plasma calcium levels ( $p=6x10^{-13}$ ) and
- 62 lower fasting glucose (p=0.02). PheWAS did not identify any safety concerns.
- 63 Conclusion: This Mendelian randomization analysis provides human-centric insight to guide clinical
- 64 development of an SLC13A5 inhibitor. We identify plasma calcium and citrate as biologically plausible
- biomarkers of target engagement, and plasma citrate as a potential biomarker of mechanism of
- action. Our human genetic evidence corroborates evidence from various animal models to support
- 67 effects of SLC13A5 inhibition on improving kidney function. Further study in the form of early-stage
- 68 clinical trials may now be warranted to help translate these findings towards improving patient care.
- 69

### 70 Key words

71 SLC13A5, citrate, kidney, renal function, Mendelian randomization, drug development

72	Acronyms

- 73 BUN: blood urea nitrogen
- 74 CI: confidence interval
- 75 CKD: chronic kidney disease
- 76 CRP: c-reactive protein
- 77 eGFR: estimated glomerular filtration rate
- 78 FDR: false-discovery rate
- 79 GWAS: genome-wide association study
- 80 HDLc: high-density lipoprotein cholesterol
- 81 IL6: interleukin-6
- 82 IVW: inverse-variance weighted
- 83 LDLc: low-density lipoprotein cholesterol
- 84 OR: odds ratio
- 85 PheWAS: phenome-wide association study
- 86 SD: standard deviation
- 87 SNP: single-nucleotide polymorphism
- 88 uACR: urine albumin-creatinine ratio

#### 89 Introduction

- 90 The kidney is a highly metabolically active organ. The provision of citric acid cycle intermediates has
- ameliorated renal tubular damage and progression of chronic renal injury in animal models [1–3].
- 92 Solute carrier family 13 member 5 (SLC13A5), which is primarily expressed in hepatocytes of the liver,
- 93 is a membrane-bound Na<sup>+</sup>-coupled co-transporter responsible for moving extracellular citrate into
- 94 the cytosol [4,5]. Systemic SLC13A5 inhibition could augment citrate flux to the kidney, thereby
- supporting renal energy metabolism. Moreover, given the role of citrate in regulating glucose
- 96 metabolism, lipid metabolism, and inflammation, SLC13A5 inhibition could indirectly affect renal
- 97 health [6–13]. However, no SLC13A5 inhibitor has yet entered clinical study, and so evidence of its
- 98 efficacy for ameliorating progression of kidney disease in humans is limited. Additionally, SLC13A5
- 99 shows species-specific effects [11,14–16].
- 100 Insights from human genetic data offer a powerful opportunity to prioritize and inform the design of 101 clinical research. Given that learnings from such genetic analyses relate to the target organism, 102 namely humans, they are well-placed to overcome some of the limitations of translating findings 103 from animal models [17]. As genes code for proteins and proteins make up the majority of drug 104 targets, it follows that naturally occurring variation in the genes coding for drug target proteins can 105 be leveraged to inform on the effect of their pharmacological perturbation [18]. The random 106 allocation of genetic variants at conception means that their association with clinical traits and 107 phenotypes are less susceptible to the confounding factors and reverse causation bias that can 108 hinder causal inference in traditional epidemiological study designs. The current availability of 109 publicly accessible large-scale genetic association data also means that such a drug-target Mendelian 110 randomization paradigm is a relatively fast and cost-effective approach for inferring the potential 111 clinical effects of perturbing drug targets [19].
- Given the pre-clinical evidence supporting potential therapeutic applications of SLC13A5 inhibition
- 113 [10,12,13,20,21], we sought to investigate its effects using drug target Mendelian randomization. By
- 114 utilizing the known effect of SLC13A5 inhibition on increasing plasma citrate levels to identify genetic
- instruments [10,22,23], our primary objective was to investigate its effects on parameters of kidney
   function. In secondary analyses, we aimed to unravel potential mechanisms of action, as well as
- evidence of broader effects on glucose and lipid metabolism, and inflammation. Such insights would
- 118 thus serve to inform and prioritize clinical development efforts for SLC13A5 inhibitors.

#### 119 Methods

#### 120 Study design overview

Genetic instruments for SLC13A5 inhibition were first identified as minimally correlated (r<sup>2</sup><0.1)</li>
 single-nucleotide polymorphisms (SNPs) within 200kB of the *SLC13A5* gene (chromosome 17, base

position 6,588,032 to 6,616,886 on reference panel GRCh37/hg19 by Ensembl) that associate with

124 plasma citrate levels at a genome-wide significance level (p<5x10<sup>-8</sup>). Instrument validity was affirmed

by performing Mendelian randomization to explore associations with plasma calcium levels, whose

126 levels are postulated to be increased with SLC13A5 inhibition due to reduced sequestration in the

- bone [24]. Such an association would also support plasma calcium as a biomarker of target
- 128 engagement for SLC13A5 inhibition.
- 129 Primary Mendelian randomization analyses were then performed to investigate the association of
- 130 genetically proxied SLC13A5 inhibition with creatinine and cystatin C based measures of estimated
- 131 glomerular filtration rate (eGFR), blood urea nitrogen (BUN), urine albumin-creatinine-ratio (uACR),
- and risk of microalbuminuria and chronic kidney disease (CKD).
- 133 To investigate whether any effect of SLC13A5 inhibition on parameters of kidney function may be
- attributable to metabolic effects in the plasma that consequently affect kidney function,
- 135 metabolome-wide Mendelian randomization of the plasma and urine was undertaken for SLC13A5
- 136 inhibition. Evidence of concordant effects of SLC13A5 inhibition on biomarkers measured in the

137 plasma and urine would be consistent with metabolic effects resulting in compensatory mechanisms

- in the kidney, whereas evidence of contrasting effects in the plasma and urine would suggest a
- 139 process specific to the kidney underlying the effects.
- 140 Secondary Mendelian randomization analyses were performed to explore the human genetic
- 141 evidence for effects of SLC13A5 inhibition on biomarkers of glucose and lipid metabolism, and
- 142 inflammation, namely plasma low-density lipoprotein cholesterol (LDLc), high-density lipoprotein
- 143 cholesterol (HDLc), triglycerides, fasting glucose, interleukin 6 (IL6) and C-reactive protein (CRP).
- 144 Finally, given that SLC13A5 is predominantly expressed in the liver and is involved in glucose and lipid
- 145 metabolism [10,12,20,25], we also investigated potential effects on liver fat.
- 146 In order to gain potential insight into mediating mechanisms and pathways implicated in the effects
- 147 of SLC13A5 inhibition, we also performed a proteome-wide Mendelian randomization study. Finally,
- to investigate potential on-target adverse effects or novel indications, we performed a phenome-
- 149 wide association study (PheWAS) [26].
- To explore whether plasma citrate is a potential mediating mechanism for any associations identified, and thus could serve as a biomarker of mechanism of action, all analyses that considered genetically
- 152 proxied SLC13A5 as the exposure were also repeated for genetically predicted plasma citrate levels,
- by selecting instruments from throughout the genome rather than confined to the *SLC13A5* gene
- 154 region.
- 155 A schematic figure depicting the overall study design is presented in Figure 1.
- 156
- 157 Statistical analysis
- 158 Instrument strength

- 159 Instrument strength was estimated by calculating the F-statistic for each SNP using the chi-squared
- approximation, which for each variant is the square of the SNP-exposure association estimate
- divided by the square of the SNP-exposure association estimate's standard error [27].
- 162

#### 163 Mendelian randomization

164 The genome-wide association study summary data sources used for the Mendelian randomization

analyses are presented in Table 1 [28–38]. Participant consent and ethical approval for all data wereobtained in the original studies.

167 The main Mendelian randomization analyses were performed using the random-effects inverse-

168 variance weighted (IVW) method [39]. This meta-analyses the Wald ratio estimates for each

- 169 instrument SNP using a random-effects inverse-variance model. After harmonising SNPs by their
- 170 effect alleles, the Wald ratio estimate is calculated by dividing the SNP-exposure association estimate
- by the SNP-outcome association estimate. The standard error of the Wald ratio estimate was
- 172 calculated using the propagation of error method.

173 Two Mendelian randomization statistical sensitivity analyses were employed, Egger and weighted 174 median, which make distinct assumptions regarding the inclusion of pleiotropic variants. The Egger 175 method regresses the SNP-outcome association estimates on the SNP-exposure association 176 estimates [40]. The slope of the regression provides a Mendelian randomization estimate that is 177 corrected for pleiotropic associations of the genetic variants and the intercept serves as a test for the 178 presence of such pleiotropic associations, provided that the magnitudes of these pleiotropic 179 associations are not correlated to instrument strength. The weighted median method orders the 180 Wald ratio estimates for all instrument SNPs weighted by their precision, and selects the median 181 value, with 95% confidence intervals (95% CIs) calculated by bootstrapping [41]. It provides an 182 accurate Mendelian randomization estimate when more than half the information for the analysis 183 comes from valid instruments. Heterogeneity in MR estimates derived from individual SNPs can also 184 signify the presence of potential bias from pleiotropy and was assessed using the Cochran's Q test 185 [42]. All Mendelian randomization analyses were performed using the "MendelianRandomization" 186 package for R statistical software [43].

187

#### 188 *Phenome-wide association study*

189 PheWAS was performed in the UK Biobank, a prospective cohort study initiated in 2006 that

recruited more than 500,000 participants aged between 40 and 69 years [44]. Participants

191 contributed phenotypic and genetic data, as well as biological samples, as previously reported [45].

192 UK Biobank has approval from the North West Multi-centre Research Ethics Committee and all

193 participants provided appropriate consent.

194 PheWAS statistical analysis was performed by first constructing a weighted genetic risk score for the 195 exposure using the same instrument SNPs as employed in the Mendelian randomization analysis. For 196 each individual included in the analysis, the number of plasma citrate-increasing alleles for each 197 instrument SNP were multiplied by the corresponding genetic association estimate with citrate for 198 that SNP, before combining by addition. International Classification of Diseases versions 9 and 10 199 were used to ascertain cases in the UK Biobank Hospital Episode Statistics data, with diagnoses 200 linked to the phenotype code (phecode) grouping system to facilitate classification of clinically 201 relevant traits [46]. Logistic regression was performed for each phecode against the standardized

- 202 genetic risk score for the exposure, adjusting for age, sex, and the first 10 genetic principal
- 203 components of genetic ancestry. Only phecodes with 200 or more cases were included in the
- analysis, to avoid inclusion of outcomes with low statistical power. PheWAS estimates are reported
- 205 per 1-SD higher standardized exposure genetic risk score. PheWAS was conducted using the
- 206 "PheWAS" package of R statistical software [47].
- 207

## 208 Statistical significance ascertainment

- 209 To account for testing of multiple outcomes in the primary Mendelian randomization analysis of
- 210 renal outcomes, the Benjamini–Hochberg false discovery rate (FDR) 5% threshold was used. No
- statistical significance threshold was used for the other analyses, which were exploratory in nature.
- All presented p-values are uncorrected for multiple testing, unless otherwise stated.
- 213

## 214 Comparison of SLC13A5 inhibition with higher plasma citrate levels by any mechanism

215 The Mendelian randomization and PheWAS analyses were also performed considering the exposure

of plasma citrate levels, rather than SLC13A5 inhibition. Selection of genetic variants to serve as

instruments and build the weighted genetic risk score for plasma citrate was undertaken using the

same approach as for SLC13A5 inhibition, except that selection of variants was not confined to the
 *SLC13A5* gene region.

220

## 221 Correlation between plasma and urine metabolome-wide Mendelian randomization results

- 222 To measure the correlation between the plasma and urine metabolome-wide Mendelian
- randomization z-score results, comparison was restricted to all those metabolites analysed in both
- plasma and urine, and associated with genetically proxied SLC13A5 inhibition at FDR p < 0.2 in either
- 225 analysis.

226

## 227 Availability of code and data

R statistical software was used for all analyses. The statistical code used in this work is available upon

reasonable request to the corresponding author. All genome-wide association study summary data

are publicly available from the sources cited in Table 1. UK Biobank individual participant data are

available upon appropriate application to the UK Biobank study. This work was reported using the

232 "Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian

233 Randomization" (STROBE-MR) checklist (Supplementary checklist) [48].

#### 234 Results

A total of 13 SNPs were identified as instruments for SLC13A5 inhibition (Supplementary Table 1), all of which had F-statistics > 10, consistent with low risk of weak instrument bias that might affect the

237 conclusions of Mendelian randomization analyses.

238 The main IVW Mendelian randomization identified positive associations of genetically proxied

239 SLC13A5 inhibition with plasma calcium levels. Every 1-SD higher genetically proxied plasma citrate

through SLC13A5 inhibition was associated with a 0.132 SD units higher plasma calcium level (95% Cl
 0.107 to 0.157, p=6x10<sup>-13</sup>).

Figure 2 depicts the associations of genetically proxied SLC13A5 inhibition with kidney function

243 parameters from the main IVW Mendelian randomization analysis. There were statistically significant

associations of genetically proxied SLC13A5 inhibition with higher creatinine and cystatin C based

245 measures of eGFR (FDR adjusted p values = 0.006 and 0.01 respectively), and lower BUN (FDR

adjusted p value = 0.002). There were no strong associations of genetically proxied SLC13A5

inhibition with uACR (FDR adjusted p value = 0.682), or risk of CKD (FDR adjusted p value = 0.516) or

248 microalbuminuria (FDR adjusted p value = 0.682).

249 The results of the metabolome-wide Mendelian randomization analysis investigating the effects of

250 SLC13A5 inhibition on plasma and urine metabolites are presented in Supplementary Tables 2 and 3.

251 For the 7 metabolites present in both analyses and associated with genetically proxied SLC13A5

252 inhibition at FDR p < 0.2 in either analysis (citrate, aconitate, acetylspermidine, alpha-

253 hydroxyisocaproate, propyl 4-hydroxybenzoate sulfate, (2-butoxyethoxy)acetic acid, 8-

254 methoxykynurenate), the correlation coefficient of their z-scores in the analysis of plasma and urine 255 was 0.78 (p=0.04).

The main IVW Mendelian randomization analysis results measuring the association of genetically proxied SLC13A5 inhibition with parameters of glucose and lipid metabolism, and inflammation are presented in Figure 3. In this hypothesis-generating analysis, there were no significant associations

258 presented in Figure 3. In this hypothesis-generating analysis, there were no significant associations 259 after adjusting for multiple testing, but some evidence to support possible associations of SLC13A5

260 inhibition with lower fasting glucose levels (-0.026 mmol/l per 1-SD higher plasma citrate through

261 SCL13A5 inhibition, 95% Cl -0.047 to 0.004, raw p=0.022). Neither proteome-wide Mendelian

randomization (Supplementary Table 4) nor PheWAS (Supplementary Table 5) identified any

significant associations for genetically proxied SLC13A5 inhibition after correcting for multipletesting.

265 All analyses were also performed considering higher plasma citrate through any mechanism as the 266 exposure, instead of genetically proxied SLC13A5 inhibition (i.e., SNPs associated with higher plasma 267 citrate selected as in the analysis for SLC13A5, but not restricted to 200kB within the SLC13A5 gene). 268 The SNPs used as instruments for plasma citrate are presented in Supplementary Table 6, and the 269 analysis results are presented in Supplementary Tables 7-10. Although the main IVW analysis did not 270 identify evidence supporting associations of genetically predicted plasma citrate levels with eGFR or 271 BUN, the Egger and weighted median sensitivity analyses that are more robust to the inclusion of 272 pleiotropic SNPs were more supportive of such an association (Supplementary Table 11). This 273 suggests that the genetic variants that affect plasma citrate are heterogeneous in the mechanisms by 274 which they achieve this, and consistent with this, there was strong evidence of heterogeneity in all 275 the IVW MR analyses undertaken with plasma citrate as the exposure (Supplementary Table 11).

#### 276 Discussion

277 Using large-scale genetic association data, we identified a genetic instrument for SLC13A5 inhibition 278 that we leveraged in the Mendelian randomization paradigm to provide clinically translatable 279 insights. Our main findings generated human genetic evidence that supports higher plasma citrate 280 and calcium as biologically plausible biomarkers of target engagement, higher plasma citrate as a 281 potential mechanism of action, and favourable effects on parameters of kidney function, namely 282 creatinine and cystatin C based measures of eGFR, and BUN. Of note, we did not identify statistically 283 significant evidence of effects of SLC13A5 inhibition on uACR nor risk of microalbuminuria. This 284 discrepancy may be explained by these biomarkers measuring different domains of kidney function 285 [49]. Of relevance, calcium citrate treatment in an acute kidney damage animal model resulted in 286 significantly reduced levels of proteinuria [1]. The primary Mendelian randomization analysis also did 287 not identify evidence of SLC13A5 inhibition having effects on CKD risk, which may in part be 288 explained by the pathophysiological heterogeneity underlying CKD [50], and SLC13A5 inhibition 289 potentially only being relevant to some of these mechanisms.

290 The correlation between the associations of genetically proxied SLC13A5 with the plasma and urine 291 metabolomes is consistent with effects of SLC13A5 on the urine being downstream to effects on the 292 plasma, and the kidney compensating plasma changes through altered renal excretion. This would 293 also support that effects of SLC13A5 inhibition on kidney function may be occurring through 294 metabolic effects originating outside the kidney. Secondary Mendelian randomization analyses 295 supported potential effects of SLC13A5 inhibition on reducing fasting glucose. Given that SLC13A5 is 296 predominantly expressed in the liver [25], these findings are consistent with direct hepatic effects. 297 The lack of strong associations of genetically proxied SLC13A5 inhibition with clinical outcomes in 298 PheWAS is reassuring regarding safety profile. This suggests smaller reductions in SLC13A5 activity 299 are unlikely to recapitulate the autosomal-recessive epileptic encephalopathy phenotype observed 300 with rare mutations affecting critical regions of the SLC13A5 gene [51].

301 SLC13A5 is a membrane-bound citrate transporter, and its inhibition results in reduced entry of 302 plasma citrate into the cytosol [4,5]. This would be expected to have implications for cellular metabolism in cells expressing SLC13A5, with the higher circulating plasma citrate levels also 303 304 potentially impacting metabolism systemically. Consistent with the results of our main genetic 305 analyses, previous work has identified protective effects of citrate in various animal models of kidney 306 disease [1,6,52,53]. Although the main IVW Mendelian randomization analysis investigating effects 307 of plasma citrate levels did not identify evidence supporting effects on parameters of kidney 308 function, there was strong evidence of heterogeneity in estimates generated by individual SNPs, 309 consistent with the presence of pleiotropic effects that could bias the main IVW analyses [42]. 310 Furthermore, the Egger and weighted median Mendelian randomization statistical sensitivity 311 analyses, which can be more robust to the inclusion of pleiotropic variants, produced estimates more 312 suggestive of favourable effects of higher plasma citrate on measures of kidney function. This 313 observation may suggest that plasma citrate is a heterogeneous trait that is affected through several 314 distinct pathways, and that at least some of these may favourably impact kidney function. This would 315 be in-keeping with the favourable effects of SLC13A5 on kidney function occurring through its effects 316 on plasma citrate. It has been reported that low citrate levels in urine are associated with various 317 forms of kidney disease, and low urinary citrate is a biomarker for kidney disease progression [52,54– 318 59]. Furthermore, preclinical studies with SLC13A5 knockout mice have supported effects on 319 sympathoadrenal mechanisms [60], which may also contribute to nephroprotective effects of 320 genetically proxied SLC13A5 inhibition.

321 There are several hypotheses for how citrate may exert its beneficial effects on kidney function.

- 322 Generally, elevated plasma citrate levels are proposed to lead to increased excretion of citrate
- through the urine. Higher urinary citrate may in turn provide an additional energy supply for kidney
- 324 cells, potentially enhancing their resilience and function. Furthermore, citrate may contribute to
- supporting the biosynthesis of essential molecules such as glucose, lipids, and amino acids.
- Additionally, it is known, due to its alkalinizing function citrate contributes to improved acid-base
- 327 balance within the kidneys, promoting a favourable environment for cellular processes. Finally,
- 328 urinary citrate's solubilizing properties might offer protection against vascular calcification and the
- 329 formation of kidney stones, thus safeguarding kidney health.
- 330 This work has several strengths. By leveraging large-scale genetic association data within the Mendelian randomization paradigm, we were able to rapidly perform several hypothesis-driven and 331 332 hypothesis-free genetic analyses relevant to humans, and consequently generate insight related to 333 drug development. Our findings represent numerous potential learnings, including highlighting 334 higher plasma citrate and calcium as a biomarker of target engagement, higher plasma citrate as a 335 biomarker of mechanism of action, efficacy for reducing progression of kidney disease, general safety 336 profile, and potential effects on reducing fasting glucose. Further, the random allocation of genetic 337 variants at conception means that these findings are less vulnerable to the confounding and reverse 338 causation bias that can hinder causal inference in traditional epidemiological study designs [61].
- 339 This work should also be interpreted in the context of its limitations. The Mendelian randomization 340 paradigm considers small lifelong effects of germline genetic variation. This is not the same as a 341 discrete clinical intervention in later life, which may be of shorter duration but larger magnitude. 342 Thus, it is possible that some of the findings of these genetic analyses may not predict what is 343 observed with inhibition of SLC13A5 in clinical practice, particularly in quantitative terms. Further, 344 some of our current analyses may also be limited by phenotypic definition and statistical power. 345 While challenges in estimating the variance of drug target perturbation predicted by genetic variants 346 means that it is not possible to perform conventional power calculations for drug target Mendelian 347 randomization [62], some indication of the relative statistical power available for each analysis is 348 apparent from the size of the 95% CIs. From this, it is clear that the analyses considering CKD had 349 much less power than those considering measures of eGFR or BUN, for example. Of relevance, 350 numerous preclinical mechanistic studies have demonstrated a role of SLC13A5 in favourably 351 affecting hepatic lipid and glucose metabolism [10–13,20,21,63,64], and the limitations of our 352 current analyses may explain the discrepancy in findings. The plasma and urine metabolome-wide Mendelian randomization analyses were undertaken using outcome data obtained from a CKD 353 354 population and may thus be vulnerable to collider bias [65]. This is because stratifying on a collider 355 can introduce associations with confounding factors. Our Mendelian randomization evidence 356 supports effects of SLC13A5 inhibition on parameters of kidney function, in-keeping with CKD 357 therefore representing a potential collider. While there are strategies available to help explore 358 potential bias from this [66], they either require individual participant data, which were not available 359 for the current Mendelian randomization analyses, or have other prohibitive limitations [67]. Finally, 360 the genetic analyses undertaken in this work provide insight into the on-target effects of perturbing 361 SLC13A5 [19], but cannot directly inform on the effects of any pharmacological agents used to inhibit 362 SLC13A5, including their pharmacokinetic and pharmacodynamic properties, or off-target effects.
- In summary, this Mendelian randomization analysis provides novel human-centric insight to guide
   the clinical development of an SLC13A5 inhibitor. We identify biologically plausible biomarkers of
   target engagement and mode of action, as well as genetic evidence supporting potential effects in
   improving kidney function, with higher plasma citrate levels a possible underlying mechanism. The

- 367 null PheWAS findings are reassuring in that they do not identify any safety signals. Further study in
- 368 the form of early-stage clinical trials may now be warranted to help translate these findings towards
- 369 improving patient care.

### 370 References

371 372 373	[1]	Gadola L, Noboa O, Marquez MN, Rodriguez MJ, Nin N, Boggia J, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004;65. https://doi.org/10.1111/j.1523-1755.2004.00496.x.
374 375 376 377	[2]	Weinberg JM, Venkatachalam MA, Roeser NF, Saikumar P, Dong Z, Senter RA, et al. Anaerobic and aerobic pathways for salvage of proximal tubules from hypoxia-induced mitochondrial injury. Am J Physiol Renal Physiol 2000;279. https://doi.org/10.1152/ajprenal.2000.279.5.f927.
378 379 380 381	[3]	Feldkamp T, Kribben A, Roeser NF, Senter RA, Weinberg JM. Accumulation of nonesterified fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxia-reoxygenation. Am J Physiol Renal Physiol 2006;290. https://doi.org/10.1152/ajprenal.00305.2005.
382 383 384	[4]	Zhang L, Hu W, Qiu Z, Li Z, Bian J. Opportunities and Challenges for Inhibitors Targeting Citrate Transport and Metabolism in Drug Discovery. J Med Chem 2023. https://doi.org/10.1021/acs.jmedchem.3c00179.
385 386 387	[5]	Inoue K, Zhuang L, Maddox DM, Smith SB, Ganapathy V. Human sodium-coupled citrate transporter, the orthologue of Drosophila Indy, as a novel target for lithium action. Biochemical Journal 2003;374. https://doi.org/10.1042/BJ20030827.
388 389 390	[6]	Bienholz A, Reis J, Sanli P, De Groot H, Petrat F, Guberina H, et al. Citrate shows protective effects on cardiovascular and renal function in ischemia-induced acute kidney injury. BMC Nephrol 2017;18. https://doi.org/10.1186/s12882-017-0546-1.
391 392 393	[7]	Akhtar MJ, Khan SA, Kumar B, Chawla P, Bhatia R, Singh K. Role of sodium dependent SLC13 transporter inhibitors in various metabolic disorders. Mol Cell Biochem 2023;478. https://doi.org/10.1007/s11010-022-04618-7.
394 395 396	[8]	Willmes DM, Kurzbach A, Henke C, Schumann T, Zahn G, Heifetz A, et al. The longevity gene INDY (I'm Not Dead Yet) in metabolic control: Potential as pharmacological target. Pharmacol Ther 2018;185. https://doi.org/10.1016/j.pharmthera.2017.10.003.
397 398 399	[9]	Schumann T, König J, Henke C, Willmes DM, Bornstein SR, Jordan J, et al. Solute carrier transporters as potential targets for the treatment of metabolic disease. Pharmacol Rev 2020;72. https://doi.org/10.1124/pr.118.015735.
400 401 402 403	[10]	Birkenfeld AL, Lee HY, Guebre-Egziabher F, Alves TC, Jurczak MJ, Jornayvaz FR, et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metab 2011;14. https://doi.org/10.1016/j.cmet.2011.06.009.
404 405 406	[11]	von Loeffelholz C, Lieske S, Neuschäfer-Rube F, Willmes DM, Raschzok N, Sauer IM, et al. The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism. Hepatology 2017;66. https://doi.org/10.1002/hep.29089.
407 408 409	[12]	Zahn G, Willmes DM, El-Agroudy NN, Yarnold C, Jarjes-Pike R, Schaertl S, et al. A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity. Metabolites 2022;12. https://doi.org/10.3390/metabo12080732.

410 411 412	[13]	Huard K, Brown J, Jones JC, Cabral S, Futatsugi K, Gorgoglione M, et al. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). Sci Rep 2015;5. https://doi.org/10.1038/srep17391.
413 414 415	[14]	Kopel JJ, Bhutia YD, Sivaprakasam S, Ganapathy V. Consequences of NaCT/SLC13A5/mINDY deficiency: Good versus evil, separated only by the blood-brain barrier. Biochemical Journal 2021;478. https://doi.org/10.1042/BCJ20200877.
416 417 418 419	[15]	Gopal E, Babu E, Ramachandran S, Bhutia YD, Prasad PD, Ganapathy V. Species-specific influence of lithium on the activity of SLC13A5 (NACT): Lithium-induced activation is specific for the transporter in primates. Journal of Pharmacology and Experimental Therapeutics 2015;353. https://doi.org/10.1124/jpet.114.221523.
420 421 422	[16]	Inoue K, Zhuang L, Ganapathy V. Human Na+-coupled citrate transporter: Primary structure, genomic organization, and transport function. Biochem Biophys Res Commun 2002;299. https://doi.org/10.1016/S0006-291X(02)02669-4.
423 424 425	[17]	Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep 2019;9. https://doi.org/10.1038/s41598-019-54849-w.
426 427 428	[18]	Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res 2021;6. https://doi.org/10.12688/wellcomeopenres.16544.2.
429 430 431	[19]	Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V, et al. Using genetic association data to guide drug discovery and development: Review of methods and applications. Am J Hum Genet 2023;110. https://doi.org/10.1016/j.ajhg.2022.12.017.
432 433 434 435	[20]	Pesta DH, Perry RJ, Guebre-Egziabher F, Zhang D, Jurczak M, Fischer-Rosinsky A, et al. Prevention of diet-induced hepatic steatosis and hepatic insulin resistance by second generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5). Aging 2015;7. https://doi.org/10.18632/aging.100854.
436 437 438 439	[21]	Brachs S, Winkel AF, Tang H, Birkenfeld AL, Brunner B, Jahn-Hofmann K, et al. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice. Mol Metab 2016;5. https://doi.org/10.1016/j.molmet.2016.08.004.
440 441	[22]	Brown TL, Nye KL, Porter BE. Growth and overall health of patients with slc13a5 citrate transporter disorder. Metabolites 2021;11. https://doi.org/10.3390/metabo11110746.
442 443 444	[23]	Bainbridge MN, Cooney E, Miller M, Kennedy AD, Wulff JE, Donti T, et al. Analyses of SLC13A5- epilepsy patients reveal perturbations of TCA cycle. Mol Genet Metab 2017;121. https://doi.org/10.1016/j.ymgme.2017.06.009.
445 446 447	[24]	Dirckx N, Zhang Q, Chu EY, Tower RJ, Li Z, Guo S, et al. A specialized metabolic pathway partitions citrate in hydroxyapatite to impact mineralization of bones and teeth. Proc Natl Acad Sci U S A 2022;119. https://doi.org/10.1073/pnas.2212178119.
448 449	[25]	Li Z, Wang H. Molecular mechanisms of the SLC13A5 gene transcription. Metabolites 2021;11. https://doi.org/10.3390/metabo11100706.

450 451 452	[26]	Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010;26. https://doi.org/10.1093/bioinformatics/btq126.
453 454	[27]	Li B, Martin EB. An approximation to the F distribution using the chi-square distribution. Comput Stat Data Anal 2002;40. https://doi.org/10.1016/S0167-9473(01)00097-4.
455 456	[28]	Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. BioRxiv 2020.
457	[29]	Neale Lab. GWAS of UK Biobank biomarker measurements 2023.
458 459 460	[30]	Stanzick KJ, Li Y, Schlosser P, Gorski M, Wuttke M, Thomas LF, et al. Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals. Nat Commun 2021;12. https://doi.org/10.1038/s41467-021-24491-0.
461 462 463	[31]	Teumer A, Li Y, Ghasemi S, Prins BP, Wuttke M, Hermle T, et al. Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria. Nat Commun 2019;10. https://doi.org/10.1038/s41467-019-11576-0.
464 465 466	[32]	Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet 2019;51. https://doi.org/10.1038/s41588-019-0407-x.
467 468 469 470	[33]	Schlosser P, Scherer N, Grundner-Culemann F, Monteiro-Martins S, Haug S, Steinbrenner I, et al. Genetic studies of paired metabolomes reveal enzymatic and transport processes at the interface of plasma and urine. Nat Genet 2023;55. https://doi.org/10.1038/s41588-023- 01409-8.
471 472 473	[34]	Graham SE, Clarke SL, Wu KHH, Kanoni S, Zajac GJM, Ramdas S, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 2021;600. https://doi.org/10.1038/s41586-021-04064-3.
474 475 476	[35]	Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet 2021;53. https://doi.org/10.1038/s41588-021-00852-9.
477 478 479	[36]	Haas ME, Pirruccello JP, Friedman SN, Wang M, Emdin CA, Ajmera VH, et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genomics 2021;1. https://doi.org/10.1016/j.xgen.2021.100066.
480 481 482	[37]	Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet 2021;53. https://doi.org/10.1038/s41588-021-00978-w.
483 484 485	[38]	Said S, Pazoki R, Karhunen V, Võsa U, Ligthart S, Bodinier B, et al. Genetic analysis of over half a million people characterises C-reactive protein loci. Nat Commun 2022;13. https://doi.org/10.1038/s41467-022-29650-5.
486 487 488	[39]	Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013;37:658–65. https://doi.org/10.1002/gepi.21758.

489 490 491	[40]	Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512– 25. https://doi.org/10.1093/ije/dyv080.
492 493 494	[41]	Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol 2016;40:304–14. https://doi.org/10.1002/gepi.21965.
495 496 497	[42]	Greco M F Del, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med 2015;34. https://doi.org/10.1002/sim.6522.
498 499 500	[43]	Yavorska OO, Burgess S. MendelianRandomization: An R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol 2017;46. https://doi.org/10.1093/ije/dyx034.
501 502 503	[44]	Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Med 2015;12. https://doi.org/10.1371/journal.pmed.1001779.
504 505 506	[45]	Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562. https://doi.org/10.1038/s41586-018-0579-z.
507 508 509	[46]	Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-CM Codes to phecodes: Workflow development and initial evaluation. JMIR Med Inform 2019;7. https://doi.org/10.2196/14325.
510 511 512	[47]	Carroll RJ, Bastarache L, Denny JC. R PheWAS: Data analysis and plotting tools for phenome- wide association studies in the R environment. Bioinformatics 2014;30. https://doi.org/10.1093/bioinformatics/btu197.
513 514 515 516	[48]	Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA - Journal of the American Medical Association 2021;326. https://doi.org/10.1001/jama.2021.18236.
517 518	[49]	Lopez-Giacoman S. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol 2015;4. https://doi.org/10.5527/wjn.v4.i1.57.
519	[50]	Matovinović MS. 1. Pathophysiology and Classification of Kidney Diseases. EJIFCC 2009;20.
520 521 522	[51]	Thevenon J, Milh M, Feillet F, St-Onge J, Duffourd Y, Jugé C, et al. Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of Life. Am J Hum Genet 2014;95. https://doi.org/10.1016/j.ajhg.2014.06.006.
523 524 525	[52]	Rocha DR, Xue L, Gomes Sousa HM, Carvalho Matos AC, Hoorn EJ, Salih M, et al. Urinary Citrate Is Associated with Kidney Outcomes in Early Polycystic Kidney Disease. Kidney360 2022;3. https://doi.org/10.34067/KID.0004772022.
526 527	[53]	Tanner GA, Tanner JA. Citrate therapy for polycystic kidney disease in rats. Kidney Int 2000;58. https://doi.org/10.1111/j.1523-1755.2000.00357.x.

528 529 530	[54]	Posada-Ayala M, Zubiri I, Martin-Lorenzo M, Sanz-Maroto A, Molero D, Gonzalez-Calero L, et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int 2014;85. https://doi.org/10.1038/ki.2013.328.
531 532 533	[55]	Hallan S, Afkarian M, Zelnick LR, Kestenbaum B, Sharma S, Saito R, et al. Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non- diabetic CKD Patients. EBioMedicine 2017;26. https://doi.org/10.1016/j.ebiom.2017.10.027.
534 535 536	[56]	Liu JJ, Liu S, Gurung RL, Ching J, Kovalik JP, Tan TY, et al. Urine tricarboxylic acid cycle metabolites predict progressive chronic kidney disease in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2018;103. https://doi.org/10.1210/jc.2018-00947.
537 538 539	[57]	Goraya N, Simoni J, Sager LN, Mamun A, Madias NE, Wesson DE. Urine citrate excretion identifies changes in acid retention as eGFR declines in patients with chronic kidney disease. Am J Physiol Renal Physiol 2019;317. https://doi.org/10.1152/ajprenal.00044.2019.
540 541 542	[58]	Mutter S, Valo E, Aittomäki V, Nybo K, Raivonen L, Thorn LM, et al. Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes. Diabetologia 2022;65. https://doi.org/10.1007/s00125-021-05584-3.
543 544 545	[59]	Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of Hypocitraturia in Recurrent Calcium Stone Formers: Focusing on Urinary Potassium Excretion. American Journal of Kidney Diseases 2006;48. https://doi.org/10.1053/j.ajkd.2006.06.008.
546 547 548	[60]	Willmes DM, Daniels M, Kurzbach A, Lieske S, Bechmann N, Schumann T, et al. The longevity gene mIndy (I'm Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms. JCI Insight 2021;6. https://doi.org/10.1172/jci.insight.136083.
549 550 551	[61]	Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess potential benefit of clinical intervention. BMJ 2012;345. https://doi.org/10.1136/bmj.e7325.
552 553 554	[62]	Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 2014;43. https://doi.org/10.1093/ije/dyu005.
555 556 557 558	[63]	Neuschäfer-Rube F, Schraplau A, Schewe B, Lieske S, Krützfeldt JM, Ringel S, et al. Arylhydrocarbon receptor-dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene-induced lipid accumulation in hepatocytes. Toxicology 2015;337. https://doi.org/10.1016/j.tox.2015.08.007.
559 560 561	[64]	Li L, Li H, Garzel B, Yang H, Sueyoshi T, Li Q, et al. SLC13A5 Is a novel transcriptional target of the pregnane x receptor and sensitizes drug-induced steatosis in human liver. Mol Pharmacol 2015;87. https://doi.org/10.1124/mol.114.097287.
562 563 564	[65]	Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. PLoS Genet 2017;13. https://doi.org/10.1371/journal.pgen.1006944.
565 566 567	[66]	Mitchell RE, Hartley AE, Walker VM, Gkatzionis A, Yarmolinsky J, Bell JA, et al. Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression. PLoS Genet 2023;19. https://doi.org/10.1371/journal.pgen.1010596.

- 568 [67] Cai S, Allen RJ, Wain LV, Dudbridge F. Reassessing the association of MUC5B with survival in
- idiopathic pulmonary fibrosis. Ann Hum Genet 2023;87:248–53.
- 570 https://doi.org/https://doi.org/10.1111/ahg.12522.

571

### 572 Acknowledgements

#### 573 Funding

- 574 This work was supported by Eternygen GmbH. Dipender Gill acknowledges support by the British
- 575 Heart Foundation Centre of Research Excellence at Imperial College London (RE/18/4/34215).
- 576 Stephen Burgess is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom
- 577 Research and Innovation Medical Research Council (MC\_UU\_00002/7).
- 578

#### 579 Conflicts of interest

- 580 Dipender Gill and Rubinder Gill are employed part-time by Primula Group. Stephen Burgess has
- 581 received personal fees from Primula Group. Andreas Birkenfeld and Jens Jordan are minor
- shareholders of Eternygen GmbH, and Grit Zahn is minor shareholder and employee of Eternygen
- 583 GmbH. Andreas Birkenfeld has received research funding from Boehringer Ingelheim und
- 584 AstraZeneca.

#### 585 Table and Figure

# Table 1. Genome-wide association study summary data used for the Mendelian randomizationanalyses.

Category	Trait	Unit	Population	Sample size	Citation
Biomarker	Plasma citrate	SD	European ancestry UK Biobank participants	115,064	[28]
	Plasma calcium	SD	British ancestry UK Biobank participants	361,194	[29]
	Creatinine-eGFR	SD of log	Multi-ancestry GWAS meta-analysis	1,201,929	
	Cystatin C-eGFR	SD of log			[30]
	Blood urea nitrogen	SD of log			
Renal	Urine albumin-creatinine ratio	SD of log	Multi-ancestry GWAS meta-analysis	564,257	[31]
	Chronic kidney disease	Log OR	Multi-ancestry GWAS meta-analysis	625,219 (64,164 cases)	[32]
	Microalbuminuria	Log OR	Multi-ancestry GWAS meta-analysis	348,954 (51,861 cases)	[31]
Metabolome	1,296 plasma metabolites	SD	German Chronic	5 022	[22]
	1,399 urine metabolites	SD	Kidney Disease study	5,025	[22]
	Plasma low-density lipoprotein cholesterol	SD	European ancestry	1,320,016	[34]
	Plasma high-density lipoprotein cholesterol	SD	GWAS meta-analysis		
	Plasma triglycerides	SD			
Lipid, glucose and	Fasting plasma glucose	mmol/l	European ancestry GWAS meta-analysis	200.622	[35]
IIIIaiiiiiatioii	Imaging-derived liver fat (MRI-PDFF)	SD	UK Biobank participants	36,703	[36]
	Plasma interleukin 6 binding aptamer level	SD	deCODE  celandic study	35,559	[37]
	Plasma C-reactive protein level	SD of log	European ancestry GWAS	427,367	[38]
Proteome	4,907 plasma protein- binding aptamers	SD	deCODE  celandic study	35,559	[37]

The full list of analysed metabolites and protein-binding aptamers are available in the Supplementary files. Full
 study details and access to GWAS summary data are provided in the original publications. BUN: blood urea
 nitrogen; eGFR: estimated glomerular filtration rate; GWAS: genome-wide association study; MRI-PDFF:

magnetic resonance imaging derived proton density fat fraction; OR: odds ratio; SD: standard deviation; uACR:
 urine albumin-creatinine ratio.

#### 593 Figure 1. Overview of the study design.

	SLC13A5 inhibition Identify genetic instruments for SLC13A5 inhibition SNPs within 200kB of the SLC13A5 gene, uncorrelated (r <sup>2</sup> <0.1) and associated with plasma citrate at p<5x10*	Higher plasma citrate Identify genetic instruments for plasma citrate SNPs from throughout the genome, uncorrelated (r <sup>2</sup> <0.1) and associated with plasma citrate at p<5x10 <sup>-8</sup>	Mendelian randomization sensitivity analyses
	Confirm Instrument validity by performing Mendelian randomization to investigate effects on plasma calcium		
Primary analysis	Hypothesis-driven Mendelian randomization analysis investigating effects on parameters of renal function Creatinine-eGFR, cystatin C-eGFR, BUN, uACR, risk of CKD and microalbuminuria		Concerned unsighted modion
Exploratory analyses	<ul> <li>Exploratory Mendelian randomization analyses investigating effects of SLC13A5 inhibition on:</li> <li>1. Plasma and urine metabolites 1,296 plasma metabolites and 1,399 urine metabolites</li> <li>2. Biomarkers of glucose and lipid metabolism, and inflammation Glucose, HDLc, LDLc and triglycerides, liver fat, IL6, CRP</li> <li>3. Plasma proteins 4,907 plasma protein-binding aptamers</li> </ul>	Repeat all analyses, but considering plasma citrate as the exposure, instead of SLC13A5 inhibition	Egger and weighted median statistical sensitivity analyses
	Phenome-wide association study 988 clinical outcomes		

594

BUN: blood urea nitrogen, CRP:C-reactive protein, CKD: chronic kidney disease; eGFR: estimated glomerular
 filtration rate, HDLc: high-density lipoprotein cholesterol, IL6: interleukin 6; LDLc: low-density lipoprotein
 cholesterol, SNP: single-nucleotide polymorphism, uACR: urine albumin-creatinine ratio.

#### 598 Figure 2. Mendelian randomization estimates for the association of genetically proxied SLC13A5

#### 599 inhibition with kidney traits.



600

Mendelian randomization estimates are scaled per 1-standard deviation (SD) increase in plasma citrate through
 genetically proxied SLC13A5 inhibition. The units for the BUN, creatinine-eGFR, cystatin C-eGFR and uACR are
 SD change in log transformed levels. The units for CKD and microalbuminuria are log odds ratio. Raw p values
 are presented. BUN: blood urea nitrogen, chronic kidney disease; eGFR: estimated glomerular filtration rate,
 urine albumin-creatinine ratio.

Figure 3. Mendelian randomization estimates for the association of genetically proxied SLC13A5

## Triglycerides -0.010, 95% CI -0.004 to 0.024, p=0.129 -0.063, 95% CI -0.134 to 0.008, p=0.076 Liver fat -LDLc --0.009, 95% CI -0.023 to 0.005, p=0.198 IL6 --0.061, 95% CI -0.132 to 0.010, p=0.086 HDLc --0.007, 95% CI -0.023 to 0.009, p=0.380 Glucose --0.026, 95% CI -0.048 to -0.004, p=0.022 CRP --0.015, 95% CI 0.039 to 0.009, p=0.216 -0.1 0.0 0.1 Mendelian randomization associations of genetically proxied SLC13A5 inhibition

607 inhibition with biomarkers of glucose and lipid metabolism, and inflammation.

608

606

609 Mendelian randomization estimates are scaled per 1-standard deviation (SD) increase in plasma citrate through 610 genetically proxied SLC13A5 inhibition. The units for fasting glucose is mmol/l, the units for C-reactive protein 611 (CRP) is standard deviation (SD) change of log transformed levels, and the remaining exposures are measured 612 in SD units. HDLc: high-density lipoprotein cholesterol, IL6: interleukin 6, LDLc: low-density lipoprotein 613 cholesterol.

614

### 615 Supplementary files

- Supplementary checklist. Strengthening the Reporting of Observational Studies in Epidemiologyusing Mendelian Randomization checklist.
- 618 Supplementary Table 1. Single-nucleotide polymorphisms used as instruments for SLC13A5
- 619 inhibition. Genetic associations with plasma citrate are presented for variants within 200kB of the
- 620 SLC13A5 gene. SNP: single-nucleotide polymorphism.
- 621 Supplementary Table 2. Metabolome-wide Mendelian randomization analysis investigating the
- associations of genetically proxied SLC13A5 inhibition with plasma metabolites. CI: confidenceinterval.
- Supplementary Table 3. Metabolome-wide Mendelian randomization analysis investigating the
   associations of genetically proxied SLC13A5 inhibition with urine metabolites. CI: confidence interval.
- 626 Supplementary Table 4. Proteome-wide Mendelian randomization analysis investigating the
- 627 associations of genetically proxied SLC13A5 inhibition with plasma protein-binding aptamers.
- 628 Supplementary Table 5. Phenome-wide association study investigating the associations of a
- 629 standardised genetic risk score for SLC13A5 inhibition with clinical outcomes across the phenome.
- Supplementary Table 6. Single-nucleotide polymorphisms used as instruments for plasma citrate
  levels, selected from throughout the genome. SNP: single-nucleotide polymorphism.
- 632 Supplementary Table 7. Metabolome-wide Mendelian randomization analysis investigating the
- associations of genetically predicted plasma citrate levels with plasma metabolites. CI: confidenceinterval.
- Supplementary Table 8. Metabolome-wide Mendelian randomization analysis investigating the
   associations of genetically predicted plasma citrate levels with urine metabolites. CI: confidence
   interval.
- Supplementary Table 9. Proteome-wide Mendelian randomization analysis investigating the
   associations of genetically predicted plasma citrate levels with plasma protein-binding aptamers.
- 640 Supplementary Table 10. Phenome-wide association study investigating the associations of a
- 641 standardised genetic risk score for plasma citrate with clinical outcomes across the phenome.
- 642 Supplementary Table 11. Mendelian randomization statistical sensitivity analyses for biomarkers of 643 renal function, glucose and lipid metabolism, and inflammation.
- 644